Eli Lilly and Company (NYSE:LLY) Shares Bought by Cyrus J. Lawrence LLC

Cyrus J. Lawrence LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 8.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 23,521 shares of the company’s stock after acquiring an additional 1,889 shares during the period. Eli Lilly and Company accounts for about 3.5% of Cyrus J. Lawrence LLC’s holdings, making the stock its 8th biggest position. Cyrus J. Lawrence LLC’s holdings in Eli Lilly and Company were worth $18,158,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Principal Financial Group Inc. grew its stake in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after buying an additional 60,306 shares during the period. Segall Bryant & Hamill LLC purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $10,115,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $1,449,000. Thompson Siegel & Walmsley LLC grew its stake in shares of Eli Lilly and Company by 18.8% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 2,549 shares of the company’s stock valued at $2,258,000 after buying an additional 403 shares during the period. Finally, HealthInvest Partners AB grew its stake in shares of Eli Lilly and Company by 12.6% during the 3rd quarter. HealthInvest Partners AB now owns 30,564 shares of the company’s stock valued at $27,078,000 after buying an additional 3,420 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $839.44 on Friday. The firm has a market cap of $795.93 billion, a PE ratio of 71.69, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The firm’s 50-day simple moving average is $835.99 and its 200-day simple moving average is $839.87. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has initiated a share buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Bank of America reaffirmed a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Truist Financial upped their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Finally, Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.